Related Experiment Videos
Aggressive intervention for myocardial infarction: angioplasty, stents, and intra-aortic balloon pumping
1Division of Cardiology, William Beaumont Hospital, Royal Oak, Michigan 48073-6769, USA.
Insights
Primary percutaneous transluminal coronary angioplasty (PTCA) is superior to thrombolysis for heart attack treatment. Stents show promise in reducing restenosis after PTCA.
Area of Science:
- Interventional Cardiology
- Cardiovascular Research
Background:
- Primary percutaneous transluminal coronary angioplasty (PTCA) benefits are not widely recognized due to limited research funding compared to pharmaceuticals.
- Existing meta-analyses and trials like GUSTO-IIB demonstrate PTCA's superiority over thrombolytic therapy in reducing mortality and reinfarction.
Purpose of the Study:
- To evaluate the effectiveness of primary PTCA in acute myocardial infarction (MI) management.
- To assess the role of prophylactic intra-aortic balloon pumping (IABP) in high-risk MI patients undergoing PTCA.
- To investigate the impact of coronary stents on restenosis rates following primary PTCA.
Main Methods:
- Review of meta-analyses and clinical trials comparing primary PTCA to thrombolysis.
- Stratification of MI patients using acute catheterization and angiographic findings.
- Randomized trial of prophylactic intra-aortic balloon pumping (IABP) in high-risk MI patients.
- Pilot study examining the use of coronary stents in conjunction with primary PTCA.
Main Results:
- Primary PTCA is proven superior to thrombolysis in reducing death and reinfarction.
- Angiographic findings significantly enhance mortality prediction compared to clinical risk factors.
- Prophylactic IABP did not improve primary endpoints or left ventricular function in high-risk MI patients.
- Coronary stents in eligible patients (69%) resulted in uncommon in-hospital events and infrequent need for repeat revascularization.
Conclusions:
- Primary PTCA is an effective treatment for acute myocardial infarction, outperforming thrombolytic therapy.
- Coronary stents represent a promising adjunctive therapy to primary PTCA, significantly reducing restenosis and the need for repeat procedures.
Abstract:
Primary percutaneous transluminal coronary angioplasty (PTCA) is not used in all hospitals capable of performing it because the data regarding results are either not known or not easily interpreted. Unlike pharmaceutical trials, which receive $30-50 million in research funds, virtually all trials of PTCA have been unfunded. Nevertheless, several groups have conclusively proved the benefit of primary PTCA over thrombolysis. In a 1995 meta-analysis, PTCA proved superior to thrombolytic therapy in reducing death and reinfarction. The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-IIB) substudy confirmed this fact with 94% certainly. Other studies were designed to refine the angioplasty technique. In the Primary Angioplasty in Myocardial Infarction (PAMI-I) study, acute catheterization was used to stratify patients and identified a low-risk population whose mortality equaled that of patients treated electively. Compared with clinical risk factors, angiographic findings enhanced the power to predict mortality three-fold. The high-risk subset with acute myocardial infarction (MI) was also randomized to treatment with or without prophylactic intra-aortic balloon pumping (IABP). Although IABP caused no complications, it had no positive effect on primary endpoints (death, recurrent MI, and reocclusion) and did not improve left ventricular function at 6 months. One limitation of primary PTCA is a high rate of late restenosis (30-50% at 6 months). In a pilot study we are examining the role of stents in conjunction with primary PTCA. Early results indicate that in the 69% of patients eligible for stent placement, in-hospital events were uncommon (no deaths, no reinfarctions, low rate of recurrent ischemia) and the need for repeat revascularization was infrequent.